Compare Eli Lilly And Co (LLY) vs Yum! Brands, Inc. (YUM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eli Lilly And Co vs Yum! Brands, Inc. — how do they compare? Eli Lilly And Co trades at $1,177.57 (market cap $1.04T), while Yum! Brands, Inc. trades at $144.69 (market cap $39.02B). The key difference: Eli Lilly And Co is far larger — about 26.7× Yum! Brands, Inc.'s market cap, and Yum! Brands, Inc. pays the higher dividend (2.1%). Which is the better fit depends on your goals — on Pluang, investors hold Eli Lilly And Co for 93 Days and Yum! Brands, Inc. for 132 Days on average.
| LLY | YUM | |
|---|---|---|
Market Cap | $1.04T | $39.02B |
Volume | 3,064,878 | 2,597,636 |
Sector | Health | Consumer Cyclical |
52-Week High | $1.28K | $168.16 |
52-Week Low | $799.57 | $135.77 |
Typical Hold Time | 93 Days | 132 Days |
Enterprise Value | $1.09T | $50.63B |
Dividend Yield | 0.59% | 2.1% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,179.27, down 0.79% on the day, with a bullish technical outlook and strong fundamental momentum. The stock has consistently beaten earnings estimates, with Q2 2026 EPS of $8.38 surpassing the $6.40 expectation. Revenue surged to $65.18 billion in 2025, driving a net income margin of 33.53%. Recent news highlights promising pipeline developments in weight-loss and diabetes drugs, reinforcing its market leadership.
The outlook remains positive given robust revenue growth, high profitability, and analyst consensus favoring buys. Key risks include competitive pressures in the obesity drug market and execution challenges in scaling production. With a consensus price target of $1,350, representing ~14% upside, the stock offers growth potential but requires monitoring of pipeline progress and market dynamics.
YUM trades at $144.82, up 3.18% today, with a bullish technical signal despite mixed indicators. Revenue grew to $8.21B in 2025, with net income of $1.56B and a strong net margin of 25.4%. The company recently sold Pizza Hut for $1.5B and announced a $0.75 dividend, reflecting strategic focus on core brands. Analysts maintain a consensus price target of $170.44, with 39% buy ratings.
YUM presents a stable investment with consistent earnings beats and dividend growth, but faces risks from high debt levels and competitive pressures. Upside is supported by analyst targets and operational efficiency, while macroeconomic headwinds and consumer spending trends pose challenges to sustained growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →About Yum! Brands, Inc.
Yum Brands is a U.S.-based restaurant operator featuring a portfolio of four brands: KFC (26,930 global units), Pizza Hut (18,380 units), Taco Bell (7,790 units), and The Habit Burger (310 units) at year-end 2021. With $58 billion in 2021 systemwide sales, the firm is the second-largest restaurant company in the world, behind McDonald's ($112.5 billion) but ahead of Restaurant Brands International ($36 billion) and Starbucks ($25 billion). Yum is 98% franchised, with the largest franchisee, Yum China, created via a 2016 spinoff transaction (after which Yum China agreed to pay 3% royalties to Yum Brands in perpetuity). Yum is the newest evolution of Tricon Brands, formerly a division of PepsiCo, and generates the bulk of its revenue from franchise royalties and marketing contributions.
Read more on YUM →
